Interferon-γ-induced neurotoxicity of human astrocytes

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 2, 2015, Pages 251-256

  Hashioka, Sadayuki ^a,b   McGeer, Edith G ^a   Miyaoka, Tsuyoshi ^b   Wake, Rei ^b   Horiguchi, Jun ^b   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

Human astrocyte; Interferon ; Neurodegenerative diseases; Neurotoxicity; Signal transducer and activator of transcription 3

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; INTERLEUKIN 1BETA; JANUS KINASE; NEUROTROPHIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT;

ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL FUNCTION; CELL SURVIVAL; DEGENERATIVE DISEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NEUROTOXICITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DRUG EFFECTS; NEUROTOXICITY SYNDROMES; PATHOLOGY;

ANTIVIRAL AGENTS; ASTROCYTES; HUMANS; INTERFERON-GAMMA; NEUROTOXICITY SYNDROMES;

EID: 84930921983     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150217122305     Document Type: Article

References (83)

1. Brambilla L, Martorana F, Rossi D. Astrocyte signaling and neurodegeneration: new insights into CNS disorders. Prion 2013; 7: 28-36.
2. Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 2011; 71: 406-24.
3. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metabol 2011; 14: 724-38.
4. Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 2010; 7: 494-506.
5. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007; 13: 54- 63.
6. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119: 7-35.
7. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28: 138-45.
8. McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Mov Disord 1997; 12: 855-8.
9. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010; 19: 355-61.
10. McGeer PL, McGeer EG. History of innate immunity in neurodegenerative disorders. Front Pharmacol 2011; 2: 77.
11. Escartin C, Bonvento G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 2008; 38: 231-41.
12. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW. Proregenerative properties of cytokine-activated astrocytes. J Neurochem 2004; 89: 1092-100.
13. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005; 50: 427-34.
14. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 2005; 4: 433-42.
15. Wang K, Bekar LK, Furber K, Walz W. Vimentin-expressing proximal reactive astrocytes correlate with migration rather than proliferation following focal brain injury. Brain Res 2004; 1024: 193- 202.
16. Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999; 23: 297-308.
17. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004; 24: 2143-55.
18. Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 2006; 129: 2761-72.
19. Menet V, Prieto M, Privat A, Gimenez y Ribotta M. Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc Natl Acad Sci USA 2003; 100: 8999-9004.
20. Wilhelmsson U, Li L, Pekna M, et al. Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci 2004; 24: 5016-21.
21. Ramon y Cajal S. Procedures in current practice on the writing of scientific papers. 1937. Clin Orthop Relat Res 2007; 455: 14-7.
22. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999; 28: 114-27.
23. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 1993; 150: 2659-67.
24. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4: 702-10.
25. Sheng WS, Hu S, Feng A, Rock RB. Reactive oxygen species from human astrocytes induced functional impairment and oxidative damage. Neurochem Res 2013; 38: 2148-59.
26. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996; 16: 276-84.
27. Liu J, Zhao ML, Brosnan CF, Lee SC. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL- 1beta and IL-1 receptor antagonist. J Immunol 1996; 157: 3569-76.
28. Li LB, Toan SV, Zelenaia O, et al. Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem 2006; 97: 759-71.
29. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec 2009; 292: 1902-13.
30. Brambilla R, Persaud T, Hu X, et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 2009; 182: 2628-40.
31. Hashioka S, Klegeris A, Schwab C, McGeer PL. Interferon-gammadependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging 2009; 30: 1924-35.
32. Hashioka S, Klegeris A, Qing H, McGeer PL. STAT3 inhibitors attenuate interferon-gamma-induced neurotoxicity and inflammatory molecule production by human astrocytes. Neurobiol Dis 2011; 41: 299-307.
33. Beach TG, McGeer EG. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. Brain Res 1988; 463: 357-61.
34. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 1988; 76: 550-7.
35. Yamada T, Kawamata T, Walker DG, McGeer PL. Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 1992; 84: 157-62.
36. Kamo H, Haebara H, Akiguchi I, Kameyama M, Kimura H, McGeer PL. A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol 1987; 74: 33-8.
37. Simpson JE, Ince PG, Lace G, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 2010; 31: 578-90.
38. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741-9.
39. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563-91.
40. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310-1.
41. Dafny N, Yang PB. Interferon and the central nervous system. Eur J Pharmacol 2005; 523: 1-15.
42. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-89.
43. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36: 180-90.
44. Popko B, Corbin JG, Baerwald KD, Dupree J, Garcia AM. The effects of interferon-gamma on the central nervous system. Mol Neurobiol 1997; 14: 19-35.
45. Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett 1988; 91: 259-64.
46. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9: 339-49.
47. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006; 197: 275-83.
48. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992; 140: 691-707.
49. Boyle EA, McGeer PL. Cellular immune response in multiple sclerosis plaques. Am J Pathol 1990; 137: 575-84.
50. Hunot S, Dugas N, Faucheux B, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999; 19: 3440-7.
51. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferongamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007; 414: 94-7.
52. Llano DA, Li J, Waring JF, et al. Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. Alzheimer Dis Assoc Disord 2012; 26: 322-8.
53. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci 2006; 27: 33-9.
54. Traugott U, Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988; 24: 243-51.
55. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol 1994; 36: 379-86.
56. Monteyne P, Van Laere V, Marichal R, Sindic CJ. Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: detection by RT-PCR without in vitro stimulation. J Neuroimmunol 1997; 80: 137-42.
57. Aebischer J, Moumen A, Sazdovitch V, Seilhean D, Meininger V, Raoul C. Elevated levels of IFNgamma and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012; 19: 752-9, e45-6.
58. Tateishi T, Yamasaki R, Tanaka M, et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol 2010; 222: 76-81.
59. Hashioka S, Klegeris A, Schwab C, Yu S, McGeer PL. Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J Neuroimmunol 2010; 225: 91-9.
60. Subramaniam PS, Torres BA, Johnson HM. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine 2001; 15: 175-87.
61. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006; 97: 439-47.
62. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 2009; 1171: 59- 76.
63. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798- 809.
64. Frisullo G, Angelucci F, Caggiula M, et al. pSTAT1, pSTAT3, and Tbet expression in peripheral blood mononuclear cells from relapsingremitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 2006; 84: 1027-36.
65. Madia F, Frisullo G, Nociti V, et al. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2009; 14: 107-17.
66. Lu JQ, Power C, Blevins G, Giuliani F, Yong VW. The regulation of reactive changes around multiple sclerosis lesions by phosphorylated signal transducer and activator of transcription. J Neuropathol Exp Neurol 2013; 72: 1135-44.
67. Shibata N, Kakita A, Takahashi H, et al. Activation of signal transducer and activator of transcription-3 in the spinal cord of sporadic amyotrophic lateral sclerosis patients. Neurodegener Dis 2009; 6: 118-26.
68. Choi JS, Kim SY, Cha JH, et al. Upregulation of gp130 and STAT3 activation in the rat hippocampus following transient forebrain ischemia. Glia 2003; 41: 237-46.
69. Choi JS, Kim SY, Park HJ, et al. Upregulation of gp130 and differential activation of STAT and p42/44 MAPK in the rat hippocampus following kainic acid-induced seizures. Brain Res Mol Brain Res 2003; 119: 10-8.
70. Su Z, Yuan Y, Cao L, et al. Triptolide promotes spinal cord repair by inhibiting astrogliosis and inflammation. Glia 2010; 58: 901-15.
71. Sriram K, Benkovic SA, Hebert MA, Miller DB, O'Callaghan JP. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? J Biol Chem 2004; 279: 19936-47.
72. Shibata N, Yamamoto T, Hiroi A, Omi Y, Kato Y, Kobayashi M. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 2010; 30: 353-60.
73. Herrmann JE, Imura T, Song B, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci 2008; 28: 7231-43.
74. Klegeris A, Bissonnette CJ, McGeer PL. Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol Aging 2005; 26: 673-82.
75. Hashioka S, Klegeris A, McGeer PL. Proton pump inhibitors reduce interferon-gamma-induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia 2011; 59: 833-40.
76. Hashioka S, Klegeris A, McGeer PL. The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-gamma. J Neuroinflammation 2012; 9: 113.
77. Hashioka S, Klegeris A, McGeer PL. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology 2012; 63: 685-91.
78. Cheng FC, Ho YF, Hung LC, Chen CF, Tsai TH. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J Chromatogr A 2002; 949: 35-42.
79. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-6.
80. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis 2010; 19: 573-89.
81. Klegeris A, Li J, Bammler TK, et al. Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia 2008; 56: 675-85.
82. Halonen SK, Woods T, McInnerney K, Weiss LM. Microarray analysis of IFN-gamma response genes in astrocytes. J Neuroimmunol 2006; 175: 19-30.
83. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 2006; 12: 829-34.